PURPOSE: To fully characterize the risk of contralateral breast cancer (CBC) in patients with breast cancer with a family history who test negative for BRCA1 and BRCA2 mutations. PATIENTS AND METHODS: From our population-based case-control study comparing women with CBC to women with unilateral breast cancer (UBC), we selected women who tested negative for BRCA1 and BRCA2 mutations (594 patients with CBC/1,119 control patients with UBC). Rate ratios (RRs) and 95% CIs were estimated to examine the association between family history of breast cancer and risk of asynchronous CBC. Age- and family history-specific 10-year cumulative absolute risks of CBC were estimated. RESULTS: Family history of breast cancer was associated with increased CBC risk; risk was highest among young women (< 45 years) with first-degree relatives affected at young ages (< 45 years; RR, 2.5; 95% CI, 1.1 to 5.3) or women with first-degree relatives with bilateral disease (RR, 3.6; 95% CI, 2.0 to 6.4). Women diagnosed with UBC before age 55 years with a first-degree family history of CBC had a 10-year risk of CBC of 15.6%. CONCLUSION: Young women with breast cancer who have a family history of breast cancer and who test negative for deleterious mutations in BRCA1 and BRCA2 are at significantly greater risk of CBC than other breast cancer survivors. This risk varies with diagnosis age, family history of CBC, and degree of relationship to an affected relative. Women with a first-degree family history of bilateral disease have risks of CBC similar to mutation carriers. This has important implications for the clinical management of patients with breast cancer with family history of the disease.
PURPOSE: To fully characterize the risk of contralateral breast cancer (CBC) in patients with breast cancer with a family history who test negative for BRCA1 and BRCA2 mutations. PATIENTS AND METHODS: From our population-based case-control study comparing women with CBC to women with unilateral breast cancer (UBC), we selected women who tested negative for BRCA1 and BRCA2 mutations (594 patients with CBC/1,119 control patients with UBC). Rate ratios (RRs) and 95% CIs were estimated to examine the association between family history of breast cancer and risk of asynchronous CBC. Age- and family history-specific 10-year cumulative absolute risks of CBC were estimated. RESULTS: Family history of breast cancer was associated with increased CBC risk; risk was highest among young women (< 45 years) with first-degree relatives affected at young ages (< 45 years; RR, 2.5; 95% CI, 1.1 to 5.3) or women with first-degree relatives with bilateral disease (RR, 3.6; 95% CI, 2.0 to 6.4). Women diagnosed with UBC before age 55 years with a first-degree family history of CBC had a 10-year risk of CBC of 15.6%. CONCLUSION: Young women with breast cancer who have a family history of breast cancer and who test negative for deleterious mutations in BRCA1 and BRCA2 are at significantly greater risk of CBC than other breast cancer survivors. This risk varies with diagnosis age, family history of CBC, and degree of relationship to an affected relative. Women with a first-degree family history of bilateral disease have risks of CBC similar to mutation carriers. This has important implications for the clinical management of patients with breast cancer with family history of the disease.
Authors: Lori J Pierce; Albert M Levin; Timothy R Rebbeck; Merav A Ben-David; Eitan Friedman; Lawrence J Solin; Eleanor E Harris; David K Gaffney; Bruce G Haffty; Laura A Dawson; Steven A Narod; Ivo A Olivotto; Andrea Eisen; Timothy J Whelan; Olufunmilayo I Olopade; Claudine Isaacs; Sofia D Merajver; Julia S Wong; Judy E Garber; Barbara L Weber Journal: J Clin Oncol Date: 2006-04-24 Impact factor: 44.544
Authors: M Robson; T Gilewski; B Haas; D Levin; P Borgen; P Rajan; Y Hirschaut; P Pressman; P P Rosen; M L Lesser; L Norton; K Offit Journal: J Clin Oncol Date: 1998-05 Impact factor: 44.544
Authors: C T M Brekelmans; M M A Tilanus-Linthorst; C Seynaeve; A vd Ouweland; M B E Menke-Pluymers; C C M Bartels; M Kriege; A N van Geel; C W Burger; A M M Eggermont; H Meijers-Heijboer; J G M Klijn Journal: Eur J Cancer Date: 2007-02-20 Impact factor: 9.162
Authors: Anne S Reiner; Julia Sisti; Esther M John; Charles F Lynch; Jennifer D Brooks; Lene Mellemkjær; John D Boice; Julia A Knight; Patrick Concannon; Marinela Capanu; Marc Tischkowitz; Mark Robson; Xiaolin Liang; Meghan Woods; David V Conti; David Duggan; Roy Shore; Daniel O Stram; Duncan C Thomas; Kathleen E Malone; Leslie Bernstein; Jonine L Bernstein Journal: J Clin Oncol Date: 2018-04-05 Impact factor: 44.544
Authors: Jada G Hamilton; Margaux C Genoff; Melissa Salerno; Kimberly Amoroso; Sherry R Boyar; Margaret Sheehan; Megan Harlan Fleischut; Beth Siegel; Angela G Arnold; Erin E Salo-Mullen; Jennifer L Hay; Kenneth Offit; Mark E Robson Journal: Breast Cancer Res Treat Date: 2017-02-01 Impact factor: 4.872
Authors: Oluwadamilola Motunaryo Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Julie A Margenthaler Journal: Ann Surg Date: 2014-12 Impact factor: 12.969
Authors: Amy L Gross; Betty J May; Jennifer E Axilbund; Deborah K Armstrong; Richard B S Roden; Kala Visvanathan Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-07-15 Impact factor: 4.254
Authors: Shoshana M Rosenberg; Michaela S Tracy; Meghan E Meyer; Karen Sepucha; Shari Gelber; Judi Hirshfield-Bartek; Susan Troyan; Monica Morrow; Lidia Schapira; Steven E Come; Eric P Winer; Ann H Partridge Journal: Ann Intern Med Date: 2013-09-17 Impact factor: 25.391
Authors: Lois B Travis; Wendy Demark Wahnefried; James M Allan; Marie E Wood; Andrea K Ng Journal: Nat Rev Clin Oncol Date: 2013-03-26 Impact factor: 66.675
Authors: Peter Angelos; Isabelle Bedrosian; David M Euhus; Virginia M Herrmann; Steven J Katz; Andrea Pusic Journal: Ann Surg Oncol Date: 2015-08-11 Impact factor: 5.344